Clinical Report: Status of Circulating Tumor DNA and Its Impact on Adjuvant Chemotherapy
Background
Colorectal liver metastasis (CRLM) is a major contributor to cancer-related mortality in colorectal cancer (CRC) patients. Despite the potential benefits of adjuvant chemotherapy (ACT) post-resection, the optimal patient selection for ACT remains unclear. The identification of biomarkers, such as ctDNA, is crucial for improving risk stratification and treatment outcomes in this patient population. Multiple studies have reported improved disease-free survival (DFS) with ACT, but a reproducible overall survival (OS) advantage has not been demonstrated, leaving the optimal selection of patients for ACT unresolved.
Data Highlights
Recent studies indicate that ctDNA levels can serve as a predictive biomarker for treatment response and recurrence risk in CRC patients. Specifically, ctDNA positivity post-surgery correlates with increased likelihood of recurrence and poorer survival outcomes. Furthermore, patients with detectable ctDNA after resection who received ACT showed improved DFS compared to those who did not.
Key Findings
ctDNA is a promising biomarker for identifying molecular residual disease (MRD) and predicting recurrence risk in CRC.
Postsurgical MRD positivity is associated with higher recurrence risk and poorer survival outcomes.
Adjuvant chemotherapy (ACT) was linked to improved disease-free survival (DFS) in patients with MRD positivity.
No significant overall survival (OS) benefit from ACT was observed in patients with MRD negativity.
The study included patients managed with both upfront surgery and neoadjuvant chemotherapy (NAC).
Clinical Implications
The findings suggest that ctDNA status could inform treatment decisions regarding adjuvant chemotherapy in patients with CRLM.
Conclusion
This analysis indicates the role of ctDNA in personalizing adjuvant chemotherapy strategies for patients with colorectal liver metastases, particularly in identifying those with molecular residual disease.
Related Resources & Content
The ASCO Post, July 2026 -- ctDNA Status May Predict Benefit From Adjuvant Chemotherapy After Resection of Colorectal Liver Metastases
The ASCO Post, March 25, 2025 -- Advancing Clinical Decisions With Circulting Tumor DNA: Insights From Recent Clinical Trials
The ASCO Post, January 2024 -- Do Patients With Molecular MRD Detected After Colorectal Cancer Surgery Benefit From Adjuvant Chemotherapy?
The ASCO Post, March 10, 2024 -- Studies Show Progress in Using ctDNA to Guide Colorectal Cancer Treatment
Circulating Tumor DNA Testing in Solid Tumors and Lymphoma: ASCO Guideline | JCO Oncology Practice
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial - PMC
Circulating Tumor DNA Status and Adjuvant Chemotherapy in Resected Colorectal Liver Metastases - PubMed
Circulating Tumor DNA Testing in Solid Tumors and Lymphoma: ASCO Guideline | JCO Oncology Practice
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial - PMC
Circulating Tumor DNA Status and Adjuvant Chemotherapy in Resected Colorectal Liver Metastases - PubMed
